Northwire Canada EditionFriday, October 16, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4170.10 +1.5% SILVER 57.16 +2.3% COPPER 6.56 −1.5% OIL 97.97 +3.0% PALLADIUM 1136.00 +3.6% LUN 32.91 +0.6% DLP 0.290 −3.3% VCV 0.065 −13.3% GG 2.89 +1.4% NBLC 0.015 +0.0% SF 0.300 −4.8% ATY 0.215 +2.4% GHL 0.060 −7.7% STND 0.060 −7.7% B 0.550 −3.5% HBM 34.33 −0.5% NTR 98.77 −0.7% SGZ 0.035 +0.0% MKA 0.670 +0.0% LXM 0.175 −18.6% CLCH 1.08 −1.8% GOLD 4170.10 +1.5% SILVER 57.16 +2.3% COPPER 6.56 −1.5% OIL 97.97 +3.0% PALLADIUM 1136.00 +3.6% LUN 32.91 +0.6% DLP 0.290 −3.3% VCV 0.065 −13.3% GG 2.89 +1.4% NBLC 0.015 +0.0% SF 0.300 −4.8% ATY 0.215 +2.4% GHL 0.060 −7.7% STND 0.060 −7.7% B 0.550 −3.5% HBM 34.33 −0.5% NTR 98.77 −0.7% SGZ 0.035 +0.0% MKA 0.670 +0.0% LXM 0.175 −18.6% CLCH 1.08 −1.8%
Management

Rize Oncology Announces Appointment Of Interim CEO

By The Northwire Desk — AI Analysis Oct 16, 2025 · 09:35 RIZE · 0.03 Rize Oncology Inc.
RIZE · Price

Executive Summary

  • Daren Graham resigns as Executive Chairman and interim Chief Executive Officer of Rize Oncology Inc.
  • Board Director P. Gage Jull is appointed as interim Chief Executive Officer pending a permanent selection.
  • The appointment is expected to be temporary while the Board evaluates candidates for the permanent CEO role.

Key Details

  • Daren Graham steps down from both the Executive Chairman and interim CEO positions effective immediately.
  • P. Gage Jull, currently serving as a Director on Rize Oncology’s board, assumes the role of interim Chief Executive Officer.
  • The Board will conduct a search to identify and appoint a permanent Chief Executive Officer; Mr. Jull’s tenure is intended to be limited.
  • No immediate operational or financial impact disclosed beyond the leadership transition.

Notable Quotes

(No direct quotes were provided in the release.)

Read the original news release →

More from Rize Oncology Inc.

Apr 13, 2026 · 16:40

Rize Oncology Announces Warrant Incentive Program

Financings